From: Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Immune effector cell-associated encephalopathy (ICE) score | |
---|---|
Orientation | Orientation to year, month, city, hospital: 4 points |
Naming | Ability to name 3 objects (e.g., point to clock, pen, button): 3 points |
Following commands | Ability to follow simple commands (e.g., “Show me 2 fingers” or “Close your eyes and stick out your tongue”): 1 point |
Writing | Ability to write a standard sentence (e.g., “Our national bird is the bald eagle”): 1 point |
Attention | Ability to count backward from 100 by 10: 1 point |
Scoring: 10, no impairment; 7–9, grade 1 ICANS; 3–6, grade 2 ICANS; 0–2, grade 3 ICANS; 0 due to the unarousable patient and unable to perform ICE assessment, grade 4 ICANS |
ASTCT grading systems of ICANS | |||||
---|---|---|---|---|---|
Items | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
ICE score | 7–9 | 3–6 | 0–2 | 0 (unarousable patient and unable to perform ICE assessment) | Death |
Depressed level of consciousness | Awakens spontaneously | Awakes to voice | Awakens only to tactile stimulus | The patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma | Death |
Seizure | N/A | N/A | Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention | Life-threatening prolonged seizure (> 5 min); or Repetitive clinical or electrical seizures without return to baseline in between | Death |
Motor findings | N/A | N/A | N/A | Deep focal motor weakness such as hemiparesis or paraparesis | Death |
Elevated ICP/cerebral edema | N/A | N/A | Focal/local edema on neuroimaging | Diffuse cerebral edema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI palsy; or papilledema; or Cushing's triad | Death |
Management | |||||
---|---|---|---|---|---|
Grade | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
Recommended management | Supportive management | Consider corticosteroid use (≤ 10 days) | Corticosteroid use (≤ 10 days) | Corticosteroid use (≤ 10 days) | N/A |